Matteo Megna (M Megna)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 194

Top Venues

Dermatologic therapy

Journal of the European Academy of Dermatology and Venereology : JEADV

Journal of clinical medicine

International journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Annunziata Raimondo, Paolo Amerio, Anna Balato, Francesco Cusano, Maria-Concetta Fargnoli, Claudio Guarneri, Luigi Ligrone, Matteo Megna, Maria Letizia Musumeci, Rosa Valentina Puca, Maria Teresa Uzzauto, Serena Lembo
Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Luigi Gargiulo, Luciano Ibba, P Malagoli, F Amoruso, Anna Balato, F Bardazzi, M Burlando, C G Carrera, P Dapavo, Valentina Dini, Francesca Maria Gaiani, Giampiero Girolomoni, C Guarneri, C Lasagni, F Loconsole, Angelo Valerio Marzano, Martina Maurelli, Matteo Megna, M Travaglini, Antonio Costanzo, A Narcisi
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis). Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Sara Cacciapuoti, Luca Potestio, Gallo Lucia, Musumeci Maria Letizia, Giacomo Caldarola, Domenico D'Amico, Caudullo Francesco, Papaianni Valeria, Clara De Simone, Ketty Peris, Matteo Megna
Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience. International journal of dermatology (2024)
Riccardo Viola, Luca Mastorino, Matteo Megna, Giovanni Damiani, Paolo Gisondi, Giuseppe Argenziano, Ketty Peris, Francesca Prignano, Martina Burlando, Andrea Conti, Francesco Loconsole, Piergiorgio Malagoli, Iris Zalaudek, Sara Cacciapuoti, Francesco Bellinato, Anna Balato, Clara De Simone, Karin Chersi, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. International journal of dermatology (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Martina Maurelli, Matteo Megna, Orsini Diego, Francesca Sampogna, Massimo Travaglini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of clinical medicine 13 (2) (2024)
Francesca Prignano, Elena Campione, Aurora Parodi, Elena Vegni, Federico Bardazzi, Riccardo G Borroni, Martina Burlando, Elisa Cinotti, Valentina Dini, Alfredo Giacchetti, Claudia Giofrè, Matteo Megna, Leonardo Zichichi, Maria-Concetta Fargnoli
EMPATHY Life in Psoriasis: Embracing Patients' Well-Being in Their Journey of Moderate-to-Severe Psoriasis. Journal of clinical medicine 13 (15) (2024)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Martina Maurelli, Matteo Megna, Orsini Diego, Francesca Sampogna, Massimo Travaglini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of clinical medicine 13 (2) (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Luca Potestio, Michela D'Agostino, Antonio Portarapillo, Valeria Esposito, Nello Tommasino, Antonia Salsano, Luigi Guerriero, Fabrizio Martora, Matteo Megna
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris. Life (Basel, Switzerland) 14 (8) (2024)
Riccardo Viola, Luca Mastorino, Matteo Megna, Giovanni Damiani, Paolo Gisondi, Giuseppe Argenziano, Ketty Peris, Francesca Prignano, Martina Burlando, Andrea Conti, Francesco Loconsole, Piergiorgio Malagoli, Iris Zalaudek, Sara Cacciapuoti, Francesco Bellinato, Anna Balato, Clara De Simone, Karin Chersi, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. International journal of dermatology 63 (3) (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Rosita Comune, Ruggiero Angelo, Antonio Portarapillo, Alessia Villani, Matteo Megna, Stefania Tamburrini, Salvatore Masala, Giacomo Sica, Fabio Sandomenico, Chandra Bortolotto, Lorenzo Preda, Mariano Scaglione
Cutaneous Squamous Cell Carcinoma: From Diagnosis to Follow-Up. Cancers 16 (17) (2024)
Matteo Megna, Anna Balato, Stefano Caccavale, Sara Cacciapuoti, Giulia Calabrese, Eugenia Veronica Di Brizzi, Luisa Di Costanzo, Raffaella Manzo, Vincenzo Marino, Rosa Valentina Puca, Francesca Romano, Oriele Sarno, Genoveffa Scotto di Luzio, Serena Lembo
Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study. Journal of clinical medicine 13 (9) (2024)
Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Maria Letizia Musumeci, Giacomo Caldarola, Domenico D'Amico, Francesco Caudullo, Valeria Papaianni, Clara De Simone, Ketty Peris, Matteo Megna
Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience. International journal of dermatology (2024)
Francesca Prignano, Elena Campione, Aurora Parodi, Elena Vegni, Federico Bardazzi, Riccardo G Borroni, Martina Burlando, Elisa Cinotti, Valentina Dini, Alfredo Giacchetti, Claudia Giofrè, Matteo Megna, Leonardo Zichichi, Maria-Concetta Fargnoli
EMPATHY Life in Psoriasis: Embracing Patients' Well-Being in Their Journey of Moderate-to-Severe Psoriasis. Journal of clinical medicine 13 (15) (2024)
Riccardo Viola, Luca Mastorino, Matteo Megna, Giovanni Damiani, Paolo Gisondi, Giuseppe Argenziano, Ketty Peris, Francesca Prignano, Martina Burlando, Andrea Conti, Francesco Loconsole, Piergiorgio Malagoli, Iris Zalaudek, Sara Cacciapuoti, Francesco Bellinato, Anna Balato, Clara De Simone, Karin Chersi, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. International journal of dermatology 63 (3) (2024)
Matteo Megna, Anna Balato, Stefano Caccavale, Sara Cacciapuoti, Giulia Calabrese, Eugenia Veronica Di Brizzi, Luisa Di Costanzo, Raffaella Manzo, Vincenzo Marino, Rosa Valentina Puca, Francesca Romano, Oriele Sarno, Genoveffa Scotto di Luzio, Serena Lembo
Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study. Journal of clinical medicine 13 (9) (2024)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Matteo Megna, Matteo Noto, Gabriella Fabbrocini, Luigi Fornaro
A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab. The Australasian journal of dermatology 64 (1) (2023)
Francesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, Stefano Piaserico, Clara De Simone, Giovanni Damiani, Giuseppe Argenziano, Marina Venturini, Paolo Dapavo, Antonio Costanzo, Matteo Megna, Francesca Prignano, Martina Burlando, Francesca Satolli, Andrea Carugno, Elena Pezzolo, Marco Romanelli, Aldo Cuccia, Giampiero Girolomoni
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. Vaccines 11 (4) (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, Marco Mariani, Gabriella Fabbrocini, P Quaglino, Luca Bianchi, A Parodi, Ketty Peris, C De Simone
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert opinion on biological therapy (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luca Potestio, Fabrizio Martora, Alessia Villani, Matteo Megna, Ruggiero Angelo
Comment on: "Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination" by Gambichler. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Sabatino Pallotta, Matteo Megna
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert opinion on investigational drugs (2023)
Fabrizio Martora, Claudio Marasca, Vincenzo Picone, Luigi Fornaro, Matteo Megna, Gabriella Fabbrocini
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis. Journal of clinical medicine 12 (3) (2023)
Matteo Megna, Matteo Noto, Gabriella Fabbrocini, Luigi Fornaro
A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab. The Australasian journal of dermatology (2023)
Luigi Gargiulo, Luciano Ibba, P Malagoli, R G Angileri, F Bardazzi, Nicoletta Bernardini, M Burlando, C G Carrera, Andrea Chiricozzi, P Dapavo, Valentina Dini, G Fabbrocini, F M Gaiani, Marco Galluzzo, C Giofré, C Guarneri, F Loconsole, G Malara, L Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, A Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Luca Potestio, Teresa Battista, Sara Cacciapuoti, Ruggiero Angelo, Fabrizio Martora, Luigi Fornaro, Elisa Camela, Matteo Megna
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge. Biomedicines 11 (8) (2023)
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, Marco Mariani, Gabriella Fabbrocini, P Quaglino, Luca Bianchi, A Parodi, Ketty Peris, C De Simone
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert opinion on biological therapy (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Maria-Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, Paolo Dapavo, Gabriella Fabbrocini, Paolo Gisondi, Giuseppe Micali, Anna Maria Offidani, Giovanni Pellacani, Nevena Skroza, Rosa Giuseppa Angileri, Martina Burlando, Campanati Anna, Carlo Giovanni Carrera, Andrea Chiricozzi, Andrea Conti, Clara De Simone, Vito Di Lernia, Enzo Errichetti, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Matteo Megna, Maria Letizia Musumeci, Francesca Prignano, Antonio Giovanni Richetta, Emanuele Trovato, Marina Venturini, Ketty Peris, Piergiacomo Calzavara Pinton
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement. Journal of clinical medicine 12 (10) (2023)
Fabrizio Martora, Claudio Marasca, Vincenzo Picone, Luigi Fornaro, Matteo Megna, Gabriella Fabbrocini
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis. Journal of clinical medicine 12 (3) (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19. Tropical medicine and infectious disease 8 (2) (2023)
Lidia Sacchelli, Federica Filippi, Anna Balato, Riccardo Balestri, Francesco Bellinato, Nicoletta Bernardini, L Bianchi, Martina Burlando, Campanati Anna, Marco Adriano Chessa, M Corazza, Antonella Di Cesare, V Di Lernia, F Diotallevi, Maria Esposito, Maria-Concetta Fargnoli, Paolo Gisondi, Alessandro Giunta, Katharina Hansel, Michela Magnano, Matteo Megna, Giulia Odorici, Francesca Prignano, C Potenza, G Rech, M Rovesti, Ruggiero Angelo, F Satolli, Luca Stingeni, Dino Gibertoni, F Bardazzi
PsoBioVax: A multicentric Italian case-control study of the immunological response to anti-SARS-CoV-2 vaccine among psoriatic patients under biological therapy. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19. Tropical medicine and infectious disease 8 (2) (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Luigi Gargiulo, Luciano Ibba, P Malagoli, F Amoruso, Giuseppe Argenziano, Anna Balato, F Bardazzi, M Burlando, C G Carrera, Giovanni Damiani, P Dapavo, Valentina Dini, G Fabbrocini, C Franchi, F M Gaiani, Giampiero Girolomoni, C Guarneri, C Lasagni, F Loconsole, Angelo Valerio Marzano, Martina Maurelli, Matteo Megna, D Orsini, Francesca Sampogna, M Travaglini, M Valenti, Antonio Costanzo, A Narcisi
A Risankizumab Super Responder Profile Identified by Long-term Real-Life Observation- IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Matteo Megna, Matteo Noto, Gabriella Fabbrocini, Luigi Fornaro
A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab. The Australasian journal of dermatology 64 (1) (2023)
Francesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, Stefano Piaserico, Clara De Simone, Giovanni Damiani, Giuseppe Argenziano, Marina Venturini, Paolo Dapavo, Antonio Costanzo, Matteo Megna, Francesca Prignano, Martina Burlando, Francesca Satolli, Andrea Carugno, Elena Pezzolo, Marco Romanelli, Aldo Cuccia, Giampiero Girolomoni
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. Vaccines 11 (4) (2023)
Francesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, Stefano Piaserico, Clara De Simone, Giovanni Damiani, Giuseppe Argenziano, Marina Venturini, Paolo Dapavo, Antonio Costanzo, Matteo Megna, Francesca Prignano, Martina Burlando, Francesca Satolli, Andrea Carugno, Elena Pezzolo, Marco Romanelli, Aldo Cuccia, Giampiero Girolomoni
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. Vaccines 11 (4) (2023)
Matteo Megna, Ruggiero Angelo, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of clinical medicine 12 (9) (2023)
Fabrizio Martora, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Dalbavancin for the treatment of severe hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19. Tropical medicine and infectious disease 8 (2) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Fabrizio Martora, Claudio Marasca, Vincenzo Picone, Luigi Fornaro, Matteo Megna, Gabriella Fabbrocini
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis. Journal of clinical medicine 12 (3) (2023)
Matteo Megna, Ruggiero Angelo, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of clinical medicine 12 (9) (2023)
Francesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, Stefano Piaserico, Clara De Simone, Giovanni Damiani, Giuseppe Argenziano, Marina Venturini, Paolo Dapavo, Antonio Costanzo, Matteo Megna, Francesca Prignano, Martina Burlando, Francesca Satolli, Andrea Carugno, Elena Pezzolo, Marco Romanelli, Aldo Cuccia, Giampiero Girolomoni
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. Vaccines 11 (4) (2023)
Matteo Megna, Matteo Noto, Gabriella Fabbrocini, Luigi Fornaro
A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab. The Australasian journal of dermatology 64 (1) (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19. Tropical medicine and infectious disease 8 (2) (2023)
Fabrizio Martora, Teresa Battista, Ruggiero Angelo, Massimiliano Scalvenzi, Alessia Villani, Matteo Megna, Luca Potestio
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature. Viruses 15 (7) (2023)
Ruggiero Angelo, Matteo Megna, Gabriella Fabbrocini, Fabrizio Martora
Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clinical and experimental dermatology 47 (10) (2022)
Wanda Lauro, Vincenzo Picone, Luisa Abategiovanni, Maria Vastarella, Lucia Gallo, Gabriella Fabbrocini, Matteo Megna
A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation. International journal of dermatology (2022)
Matteo Megna, Nello Tommasino, Luca Potestio, Teresa Battista, Angelo Ruggiero, Matteo Noto, Gabriella Fabbrocini, Lucia Genco
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. The Journal of dermatological treatment 33 (6) (2022)
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. The Journal of dermatological treatment 33 (5) (2022)
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Angelo Ruggiero, Matteo Megna
New frontiers in personalized medicine in psoriasis. Expert opinion on biological therapy (2022)
Kim A Papp, Henrik Thoning, Sascha Gerdes, Matteo Megna, Henrik Brandi, Marie Y Jablonski Bernasconi, Oriol Yélamos
Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. The Journal of dermatological treatment 33 (7) (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety (2022)
Fabrizio Martora, Ruggiero Angelo, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to 'Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review' by Pauluzzi et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Matteo Megna, Elisa Camela, Alessia Villani, Andrea Tajani, Gabriella Fabbrocini, Luca Potestio
Teledermatology: A useful tool also after COVID-19 era? Journal of cosmetic dermatology 21 (6) (2022)
Matteo Megna, Lucia Genco, Matteo Noto, Cataldo Patruno, Gabriella Fabbrocini, Maddalena Napolitano
Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab. Dermatologic therapy 35 (11) (2022)
Matteo Megna, Elisa Camela, Ruggiero Angelo, Gabriella Fabbrocini, Luca Potestio
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al. International journal of dermatology 61 (10) (2022)
Ruggiero Angelo, Matteo Megna, Gabriella Fabbrocini, Luigi Fornaro, Alessia Villani
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety 21 (10) (2022)
Elisa Camela, Massimiliano Scalvenzi, Matteo Megna, Luca Potestio, Gianluca Guerrasio, Luigi Fornaro, Gabriella Fabbrocini, Claudia Costa
Reply to "A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination" by Manaa et al. Dermatologic therapy (2022)
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Elisa Camela
Treating psoriasis in the elderly: biologics and small molecules. Expert opinion on biological therapy (2022)
Ruggiero Angelo, Mariateresa Nocerino, Giovanni Trischitta, Luca Costanzo, Gabriella Fabbrocini, Lucia Gallo, Matteo Megna
Persistent candidiasis infection during anti-IL-17 treatment for plaque psoriasis requiring biologic discontinuation: a case series and literature review. International journal of dermatology (2022)
Alessia Villani, Maria Carmela Annunziata, Matteo Megna, Massimiliano Scalvenzi, Gabriella Fabbrocini
Long-term results of teledermatology for acne patients during COVID-19 pandemic. Journal of cosmetic dermatology 21 (4) (2022)
Matteo Megna, Cataldo Patruno, Maria Rita Bongiorno, Alessio Gambardella, Claudio Guarneri, Caterina Foti, Serena Lembo, Francesco Loconsole, Gabriella Fabbrocini
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. The Journal of dermatological treatment 33 (5) (2022)
Matteo Megna, Luisa Abategiovanni, Alberto Annunziata, Ginevra Torta, Tiziana Peduto, Gabriella Fabbrocini, Wanda Lauro
Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient. Dermatologic therapy 35 (5) (2022)
Matteo Megna, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, Luca Potestio
Letter to the editor submitted in response to 'Should the presence of psoriatic arthritis change how we manage psoriasis?' The Journal of dermatological treatment 33 (5) (2022)
Ruggiero Angelo, Luca Potestio, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Reply to 'Nail psoriasis: A rare mRNA COVID-19 vaccine reaction' by Lamberti A et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Luca Potestio, Elisa Camela, Andrea Tajani, Gabriella Fabbrocini, Matteo Megna
Letter to the editor regarding the article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." Journal of cosmetic dermatology 21 (3) (2022)
Ruggiero Angelo, Fabrizio Martora, Vincenzo Picone, Luca Potestio, Elisa Camela, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clinical and experimental dermatology 47 (12) (2022)
Matteo Megna, Teresa Battista, Luca Potestio, Ruggiero Angelo, Virginia Ventura, Gabriella Fabbrocini, Vincenzo Picone
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. Journal of cosmetic dermatology (2022)
Claudio Marasca, Maria Carmela Annunziata, Elisa Camela, Adriana Di Guida, Luigi Fornaro, Matteo Megna, Maddalena Napolitano, Cataldo Patruno, Luca Potestio, Gabriella Fabbrocini
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. Journal of clinical medicine 11 (6) (2022)
Fabrizio Martora, Gabriella Fabbrocini, Paola Nappa, Matteo Megna
Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. International journal of dermatology 61 (7) (2022)
Ruggiero Angelo, Matteo Megna, Vincenzo Marino, Luca Costanzo, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza, Chiara Miano, Lucia Gallo
A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued? Dermatologic therapy 35 (4) (2022)
Matteo Megna, Luca Potestio, Elisa Camela, Gabriella Fabbrocini, Ruggiero Angelo
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting. Dermatologic therapy 35 (9) (2022)

Matteo Megna.css-eqlu8i{font-size:small;padding-left:4px;} (M Megna)

Publication Activity (10 Years)

Top Topics

Top Venues

Matteo Megna (M Megna)